Effect Of Peishiruanganxiaopi Pills On The Expression Of Fas And IL-18in Tumor On H22Tumor-bearing Mice

Objectives: By observing the effect of Peishiruanganxiaopi pills (PRGXP) on theexpression of Fas in tumor and IL-18in serum on H22bearing mice, we have discussedPeishiruanganxiaopi Pills on tumor induced by apoptosis, as well as on regulating the immunesystem of Tumor-bearing Mice in molecular biology. Thus, it provides a theoretical basis onclinical application.Methods: The SPF grade of72healthy Kunming Mice, half male and half female, wererandomly divided into two groups according to weight and sex,12mices in the blank group,60mices in the model group. By hypodermic inoculation in the right front axilla of mice, weestablished the tumor-bearing mice model for model group. On principle of randomization,60of tumor-bearing mice model were subdivided into five groups, each group12. They weremodel group, low dose group of PRGXP, middle dose group of PRGXP, high dose group ofPRGXP, and FufangBanmao Capsule(BM)group. Each group was dosed for twelve days andthe male and female mice were fed respectively. After24h of the last dose, the blood wasextirpated from the eyeballs of the mice, serum of which was collected after centrifugationand kept in-20℃refrigerator. In addition, the concentration of IL-18in serum was detectedby ELISA. After the mice were killed by the Bone marrow dislocated method, we peeled andweighed the tumor tissue, the thymus, the spleen, then calculated the tumor inhibiting rates,the thymus index(TI) and the spleen index(SI), made the slide of the H22tumor from themice and observed by HE technique; then we assessed the effects of PRGXP on Fas in tumorwith the method of immunohistochemistry.Results:1. Each dose group of PRGXP on H22tumor-bearing mice showed significantinhibition of tumor weight. The weight of tumor in low dose group of PRGXP, middle dosegroup of PRGXP, high dose group of PRGXP separately were (0.954±0.242)g、(0.748±0.068)g、(0.883±0.166)g, the corresponding antitumor rate were26.3%、42.2%、31.9%,which lower than the model group(P＜0.05);2. The SI and TI of each dose group of PRGXPwere higher than the model group. The TI and SI of the middle group were (53.1±8.9)mg/10gand (63.6±8.8)mg/10g, and the growth rate of TI and SI were34.1%and38.6%. Compared with the model group, there was a significantly difference (P＜0.05);3. HE staining showed:in each dose group of PRGXP karyopyknosis was obviously found, the cell division werereduced, and there were more necrosis in each dose group of PRGXP than in the model group;4. The density of the IL-18in each dose group of PRGXP were higher than the model group,the density of the IL-18of the middle and high group separately were （418.91±58.79）pg·ml-1、（366.66±97.76）pg·ml-1, which has statistic significance in comparison with themodel group P＜0.05).5. The expression of Fas in tumor on PRGXP each dose groups werehigher than the model group. Compared with the model group, PRGXP high and middle dosegroups were significantly different (P＜0.05).Conclusions: Peishiruanganxiaopiwan（PRGXP）on H22tumor-bearing mice showedsignificant inhibition of tumor cell proliferation. PRGXP can increase the SI and TI, improvethe body’s non-specific immune function. PRGXP can increase the expression of Fas in H22tumor-bearing mice to promote apoptosis; while improved serum IL-18content impacts thegrowth inhibition of tumor.